Detalles de la búsqueda
1.
Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antivirals.
J Med Virol
; 96(5): e29675, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38746997
2.
Lifetime risk of liver-related outcomes and determinants in male inactive carriers of chronic hepatitis B.
J Med Virol
; 95(10): e29138, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37796044
3.
Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV/HBV Dual Infection: A Randomized Trial.
Clin Gastroenterol Hepatol
; 20(12): 2800-2808, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34864158
4.
Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR).
Clin Gastroenterol Hepatol
; 20(5): 1151-1162.e6, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34333150
5.
The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
J Gastroenterol Hepatol
; 37(10): 1901-1910, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35790343
6.
Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors.
J Formos Med Assoc
; 121(8): 1478-1487, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34764005
7.
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.
J Formos Med Assoc
; 121(8): 1567-1578, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35123849
8.
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan.
Liver Int
; 41(6): 1265-1277, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33655714
9.
Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B-related hepatocellular carcinoma.
Mol Carcinog
; 59(11): 1269-1279, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32914490
10.
Smoking and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase.
Hepatology
; 69(4): 1412-1425, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30382583
11.
Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy.
J Formos Med Assoc
; 119(10): 1483-1489, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32653388
12.
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis.
J Gastroenterol Hepatol
; 34(11): 1977-1983, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30931537
13.
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study.
J Formos Med Assoc
; 118(6): 1014-1023, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30448077
14.
Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study.
Gastroenterology
; 153(4): 1006-1017.e5, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28711626
15.
Genome-wide identification of blood DNA methylation patterns associated with early-onset hepatocellular carcinoma development in hepatitis B carriers.
Mol Carcinog
; 56(2): 425-435, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27254796
16.
Progressive accumulation of mutations in the hepatitis B virus genome and its impact on time to diagnosis of hepatocellular carcinoma.
Hepatology
; 64(3): 720-31, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27228506
17.
Development of risk scoring system for stratifying population for hepatocellular carcinoma screening.
Hepatology
; 61(6): 1934-44, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25418332
18.
Hepatitis B virus: new therapeutic perspectives.
Liver Int
; 36 Suppl 1: 85-92, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26725903
19.
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Liver Int
; 36(12): 1755-1764, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27634134
20.
Response to letter to the editor "Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy".
J Formos Med Assoc
; 120(2): 915-917, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32843288